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Abstract
Background: Neurogenic inflammation has for decades been considered an important part of migraine
pathophysiology. In the present study, we asked the question if administration of a novel kynurenic acid analogue
(SZR72), precursor of an excitotoxin antagonist and anti-inflammatory substance, can modify the neurogenic
inflammatory response in the trigeminal ganglion.
Methods: Inflammation in the trigeminal ganglion was induced by local dural application of Complete Freunds
Adjuvant (CFA). Levels of phosphorylated MAP kinase pERK1/2 and IL-1β expression in V1 region of the trigeminal
ganglion were investigated using immunohistochemistry and Western blot.
Findings: Pretreatment with one dose of SZR72 abolished the CFA-induced pERK1/2 and IL-1β activation in the
trigeminal ganglion. No significant change was noted in case of repeated treatment with SZR72 as compared to a
single dose.
Conclusions: This is the first study that demonstrates that one dose of KYNA analog before application of CFA
can give anti-inflammatory response in a model of trigeminal activation, opening a new line for further
investigations regarding possible effects of KYNA derivates.
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Background
Neurogenic inflammation (NI) has for decades been con-
sidered an important part of migraine pathophysiology
[1]. Basic studies of NI show that it is characterized by
proinflammatory responses, caused by the stimulation of
peripheral terminals of the primary sensory neurons
located in the trigeminal ganglion [2], ultimately involved
in sensitization and allodynia. Despite growing interest on
the role of neuro-immune interactions in migraine, studies
show controversial results regarding serum cytokine levels
[3–5].
An interaction between the kynurenine pathway and
the immune system has been suggested [6]; the kynure-
ninine system by itself can be activated by inflammatory
agents and kynurenic acid has a clear antiinflammatory
effect [7]. One of the first studies demonstrating that the
kynurenine pathway has a central role in migraine, was
performed by Knyihár-Csillik and coworkers, revealed
that electrical stimulation of the trigeminal ganglion
decreased kynurenine-aminotransferase immunoreac-
tivity in rat dura mater [8]. Recent studies strengthen
the importance of the kynurenine system in case of
primary headaches, showing significant reduction in
levels kynurenic acid in patients with chronic mi-
graine [9–11].
In order to advance our understanding we have deve-
loped a method to study inflammation in the trigeminal
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ganglion induced by local dural application of Complete
Freund’s Adjuvant (CFA) [12].
In the present study we administered a novel kynurenic
acid analogue (SZR72), a glutamate antagonist, to dem-
onstrate its ability to modify this trigeminal ganglion
response and might therefore represent a future approach
to migraine treatment.
Methods
The present study is based on the animal model of indu-
cing inflammatory response in the trigeminal ganglion
via activation of the peripheral branches in the dura
mater of the trigeminal neurons [12].
Synthesis of novel KYNA derivative
The KYNA amide was designed in the Department of
Pharmaceutical Chemistry and MTA-SZTE Research
Group for Stereochemistry, University of Szeged Hungary.
The synthesis was performed by coupling of KYNA
and 2-dimethylaminoethylamine, afterwards treatment
of ethanolic hydrogen chloride, resulting N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide
hydrochloride. The structural properties of SZR72 are the
following: presence of a water-soluble side-chain, the
inclusion of a new cationic center, and side-chain sub-
stitution in order to facilitate brain penetration [6, 13].
Animals
Adult male Sprague-Dawley rats (220–300 g) (n = 49, 24
for immunohistochemistry, 25 for Western blot) were
used. The animals were maintained under standard
laboratory conditions with free access to food and tap
water. The study followed the guidelines of the European
Communities Council (86/609/ECC) and approved by
the Ethics Committee of The Faculty of Medicine,
University of Szeged, Hungary.
Operations
We have recently described the method in detail [12].
Treatments
The animals were divided into 5 groups: (i) pre-
treatment KYNA (KYNA analog 1 h before CFA admin-
istration), (ii) pre-treatment saline (saline 1 h before
CFA), (iii) repeated treatment (KYNA analog every 12 h,
for 7 days), (iv) repeated saline (saline every 12 h, for
7 days) and (v) fresh (intact, control rats) (Table 1). The
KYNA analog (300 mg/kg body weight was dissolved in
1 ml saline) or saline (1 ml) were given intraperitoneally.
As shown before [12] the “inflammatory” response to
dural CFA was studied after 1 week, left trigeminal gan-
glion was removed and the specimens were prepared for
immunohistochemistry or Western blot.
Immunohistochemistry and microscopic analysis
Immunohistochemistry was performed to demonstrate
the localization of pERK1/2 and IL-1β, and semi-
quanitatively evaluate the alterations in their expression
in the trigeminal ganglion. Details of the antibodies are
given in Table 2. The immunohistochemistry method
and the microscopic analysis were described in our
previous study [12].
Table 1 Animal groups used for immunohistochemistry and Western blot
Groups Treatment 1 h before operation Treatment every 12 hrs, for 7 days No of animals, IHC No of animals, WB
Pre-treatment SZR72 KYNA derivate - 6 5
Pre-treatment saline saline - 4 5
Repeated treatment SZR72 KYNA derivate KYNA derivate 6 5
Repeated saline saline saline 4 5
Intact control - - 4 5
Table 2 Details of primary and secondary antibodies used for IHC and WB
Name Product code Host Dilution Company
IHC
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 4376 Rabbit 1:50 Cell Signaling Technology, Danvers, MA, USA
Anti IL-1 beta antibody ab 9787 Rabbit 1:100 Abcam; Cambridge, UK
WB
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 4376 Rabbit 1:1000 Cell Signaling Technology, Danvers, MA, USA
Anti IL-1 beta antibody ab 9787 Rabbit 1:500 Abcam; Cambridge, UK
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Western blot
The method used for Western blot is described in
one of our studies [14]. Data were normalised to an
internal loading control sample to adjust for gel-to-gel




In evaluating the immunohistochemical results, the
medullary zone of the trigeminal ganglion and the V1
region were chosen.
pERK1/2
As described earlier [12], pERK1/2 immunoreactivity
was detected in a few nuclei of the neurons, including
nucleoli, in fresh animals. A few satellite glial cells
(SGC) were considered as positively stained (Fig. 1a).
In CFA treated animals i.p. saline revealed high-
intensity pERK1/2 immunoreactivity in SGCs, espe-
cially in the anteromedial zone of the ganglion
(Fig. 1b). No significant difference was noted in case
of repeated use of saline i.p.
In contrast, animals treated with the novel KYNA der-
ivate, showed abolished pERK1/2 immunoreactivity in
SGC (Fig. 1c). Repeated treatment with the KYNA ana-
log resulted in mitigation of the SGC activation com-
pared to saline treatment; both positive and negative
SGC were detected.
Blinded analysis of the SGCs fluorescence intensity
showed significant difference between the control
groups and the pre-treatment group with KYNA der-
ivate (p < 0.05). In contrast, no significant difference
between the control groups and repeated treatment
with KYNA analog was found (p = 0.069), neither be-
tween the pre-treatment and repeated treatment
groups with KYNA analog (p = 0.567).
IL-1β
As described before [12], IL-1β immunoreactivity was
observed in the neuronal cytoplasm (in a granular
manner), in a few nuclei and in the nerve fibers of
Fig. 1 pERK1/2 in the trigeminal ganglion. a In fresh animals, pERK1/2 immunoreactivity was detected in a few nuclei of the trigeminal ganglia,
including nucleoli, in fresh animals. No immunoreactivity was found in the neuronal cytoplasm. A few SGC were considered as positively stained.
b In CFA animals repeated treatment with saline i.p., high-intensity pERK1/2 immunoreactivity was observed in SGCs. c Animals treated with KYNA
for 7 days, diminished immunoreactivity to pERK1/2 in SGC
Fig. 2 IL-1β in the trigeminal ganglion. a IL-1β immunoreactivity was observed in the neuronal cytoplasm (in a granular manner), in a few nuclei
and in the nerve fibers of fresh animals. No immunoreactivity was detected in the SGC. b After i.p. treatment with saline for 7 days, increased
IL-1β immunoreactivity was observed both intracellularly in the neurons, and in the fibers. In addition, a “ring” IL-1β immunoreactivity close to
the neuronal cell membrane was evident. c Following i.p. treatment with KYNA for 7 days, the homogenous immunoreactivity close to the cell
membrane disappeared, returning to the granular cytoplasmatic pattern observed in fresh animals. No difference could be noted in the neuronal
nuclei and in fibers, and no immunoreactivity was detected in the SGC
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fresh animals. No immunoreactivity was detected in
the SGC (Figs. 2a and 3). After i.p. treatment with
saline and application of CFA, increased IL-1β immu-
noreactivity was observed both intracellularly in the neu-
rons, and in the fibers. In addition, a “ring” IL-1β
immunoreactivity close to the neuronal cell membrane
was evident, which differed from the granular pattern seen
in fresh animals (Fig. 2b).
Following i.p. treatment with KYNA analogue, the
homogenous immunoreactivity close to the cell mem-
brane disappeared, returning to the granular cyto-
plasmatic pattern observed in fresh animals. Repeated
treatment with KYNA derivate showed no difference
compared to the pretreatment with KYNA. No differ-
ence could be noted in the neuronal nuclei and in
fibers, and no immunoreactivity was detected in the
SGC (Fig. 2c).
Blinded analysis of the neuronal fluorescence in gen-
eral, but also the presence of homogenous immunofluor-
escence close to the cell membrane, showed significant
difference between control groups (pre-treatment and
repeated treatment with saline) and pre-treatment with
KYNA analog (p < 0.05). IL-1β immunoreactivity was
significantly decreased in the repeated treatment
KYNA group compared to control groups treated
with saline (p < 0.001). Between the pre-treated and
repeated treatment groups, no significant difference
could be noted (p = 0.969).
A schematic drawing of the main results for the im-
munohistochemistry is shown in Fig. 4 and results are
summarized in Table 3.
Western blot
Staining for both pERK/tERK and pro-IL-1β using
tissue lysates of complete left trigeminal ganglia did
not reveal any significant changes in expression levels
between treatment groups as analyzed by one-way
ANOVA (p = 0.8282 and p = 0.7461, respectively) with
Bonferroni multiple correction post-testing and Student’s
t-test (Fig. 5).
Discussion
The main question asked was if the KYNA derivate
could modify the CFA-induced long-term inflammatory
activation of the trigeminal ganglion, shown by increased
expression of pERK1/2 and IL-1β [12].
The role of the kynurenine pathway in the CNS is very
complex, modulating several neurotransmitters. In 1947
Beadle at al. [15] discovered that the major route for
tryptophan metabolism to nictoniamide and its conju-
gates is the kynurenine pathway. Tryptophan represents
a precursor of serotonin, a neurotransmitter playing an
important role in the migraine pathophysiology [16].
The kynurenine pathway, having several neuroactive me-
tabolites including kynurenic acid (KYNA) [17, 18], has
an important role in various diseases of the CNS [6, 19].
Astrocytes represent one source of neuroprotective
KYNA [6, 20]; KYNA was presumed to have protective
effect in neuronal cell death [21, 22]. Studies have also
suggested that an elevated extracellular KYNA level
would be needed to act more effectively [23], leading to
the idea of systemic administration of KYNA. This was
not proved to be an ideal therapeutic option, as KYNA
poorly penetrates the blood-brain barrier and it under-
goes a rapid clearance from the brain and the circulation
[24]. To overcome these difficulties new KYNA ana-
logues were synthesized to facilitate blood-brain penetra-
tion [13]. It has been shown that the analogue SZR72
has similar neuroprotective effect as KYNA and cross
more easily the BBB [25, 26].
In the present study SZR72 (1 mmol/kg bodyweight)
reduced the CFA- elevated response on pERK1/2 and
IL-1β activation in the trigeminal ganglion. The experi-
ments were designed to answer the question if in case of
chronification of migraineous mechanism (i) one dose of
SZR72 is enough to attenuate the activation or if (ii)
daily treatment would be needed.
Fig. 3 A detailed distribution of IL-1β in a trigeminal ganglion neuron
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The pERK1/2 is suggested to represent a rapid and
robust marker of activation and inflammation [27, 28],
whereas IL-1β is a late marker of maintained neuro-
pathic pain [29]. In case of using one dose of SZR72,
pERK1/2 activation in the SGC was significantly di-
minished, whereas in case of repeated treatment the
difference was not found to be significant. This find-
ing might be explained by the property of pERK1/2
as being an early marker and not an optimal sign of
prolonged activation.
The IL-1β activation was modified both after one
dose of SZR72 and after repeated treatment with
SZR72. Although no significant difference was
observed between the pre-treatment and repeated
treatments in case of IL-1β, there was a significant
difference between the repeated SZR72 treated group
and control groups. IL-1β might represent a more
proper marker to examine long term effects of
SZR72.
When it comes to our Western blot studies, the
same tendency can be followed, without any signifi-
cant difference between the groups. This might be
explained by a methodological problem: to isolate
macroscopically the V1 region is almost impossible
therefore the whole ganglia were processed in case of
WB studies. We might reasonably postulate that our
WB studies are not specific enough for the V1 region
of the trigeminal ganglion.
Table 3 Summary of results for IHC for pERK and IL-1β regarding neurons, fibers and satellite glial cells (SGC); intensity scale: “-” no
staining, “+/-” very weak staining, “+”-weak staining, “++”-moderate staining, “+++” strong staining
pERK 1/2 IL-1β
Groups Neurons (nucleolei) Fibers SGC Neurons Fibers SGC
Pre-treatment SZR72 (dura exposed to CFA) + + +/- +/- + -
Pre-treatment saline (dura exposed to CFA) + + +++ +++ + -
Repeated treatment SZR72 (dura exposed to CFA) + + ++ +/- + -
Repeated treatment saline (dura exposed to CFA) + + +++ +++ + -
Intact control (unoperated) + + +/- - + -
Fig. 4 A schematic drawing of the distribution of pERK1/2 and IL-1β
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In conclusion, this is the first study to address the
question whether daily use of the new KYNA analog
would be more effective than one dose prior activa-
tion in a chronification model of trigeminal activation.
Pretreatment with one dose was able to abolish pERK
and IL-1β activation in the trigeminal ganglion. These
findings open a new line for further investigations
which could result in a new way to modulate inflam-
mation in chronic migraine.
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